Johnson & Johnson focuses on biopharma and medtech for growth

Johnson & Johnson is positioned for potential growth through its strategic focus on biopharma and medtech following the 2023 separation of its consumer health division. Analysts suggest that by removing slower-growth consumer businesses, the company can concentrate investments on more innovative and lucrative product segments.

Recent positive sentiment is driven by durable two-year results for icotrokinra (ICOTYDE) in treating moderate-to-severe plaque psoriasis, where nearly three-quarters of participants achieved clear or almost clear skin. Financial institutions including Guggenheim and Morgan Stanley have issued Buy ratings, citing the company's drug launches and pipeline investments.

While the company maintains a strong defensive appeal for income-focused investors due to its dividend history, it faces some headwinds, including a lawsuit from Boston Scientific against J&J subsidiary Atraverse.